BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 30375428)

  • 1. A novel somatic mutation of SIN3A detected in breast cancer by whole-exome sequencing enhances cell proliferation through ERα expression.
    Watanabe K; Yamamoto S; Sakaguti S; Isayama K; Oka M; Nagano H; Mizukami Y
    Sci Rep; 2018 Oct; 8(1):16000. PubMed ID: 30375428
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Maximum growth and survival of estrogen receptor-alpha positive breast cancer cells requires the Sin3A transcriptional repressor.
    Ellison-Zelski SJ; Alarid ET
    Mol Cancer; 2010 Sep; 9():263. PubMed ID: 20920219
    [TBL] [Abstract][Full Text] [Related]  

  • 3. SIN3A and SIN3B differentially regulate breast cancer metastasis.
    Lewis MJ; Liu J; Libby EF; Lee M; Crawford NP; Hurst DR
    Oncotarget; 2016 Nov; 7(48):78713-78725. PubMed ID: 27780928
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The FOXN3-NEAT1-SIN3A repressor complex promotes progression of hormonally responsive breast cancer.
    Li W; Zhang Z; Liu X; Cheng X; Zhang Y; Han X; Zhang Y; Liu S; Yang J; Xu B; He L; Sun L; Liang J; Shang Y
    J Clin Invest; 2017 Sep; 127(9):3421-3440. PubMed ID: 28805661
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The prevalence of estrogen receptor-1 mutation in advanced breast cancer: The estrogen receptor one study (EROS1).
    Najim O; Huizing M; Papadimitriou K; Trinh XB; Pauwels P; Goethals S; Zwaenepoel K; Peterson K; Weyler J; Altintas S; van Dam P; Tjalma W
    Cancer Treat Res Commun; 2019; 19():100123. PubMed ID: 30826563
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Repression of ESR1 through actions of estrogen receptor alpha and Sin3A at the proximal promoter.
    Ellison-Zelski SJ; Solodin NM; Alarid ET
    Mol Cell Biol; 2009 Sep; 29(18):4949-58. PubMed ID: 19620290
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mutation site and context dependent effects of ESR1 mutation in genome-edited breast cancer cell models.
    Bahreini A; Li Z; Wang P; Levine KM; Tasdemir N; Cao L; Weir HM; Puhalla SL; Davidson NE; Stern AM; Chu D; Park BH; Lee AV; Oesterreich S
    Breast Cancer Res; 2017 May; 19(1):60. PubMed ID: 28535794
    [TBL] [Abstract][Full Text] [Related]  

  • 8. ESR1 mutations are frequent in newly diagnosed metastatic and loco-regional recurrence of endocrine-treated breast cancer and carry worse prognosis.
    Zundelevich A; Dadiani M; Kahana-Edwin S; Itay A; Sella T; Gadot M; Cesarkas K; Farage-Barhom S; Saar EG; Eyal E; Kol N; Pavlovski A; Balint-Lahat N; Dick-Necula D; Barshack I; Kaufman B; Gal-Yam EN
    Breast Cancer Res; 2020 Feb; 22(1):16. PubMed ID: 32014063
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Estrogen receptor α dependent regulation of estrogen related receptor β and its role in cell cycle in breast cancer.
    Madhu Krishna B; Chaudhary S; Mishra DR; Naik SK; Suklabaidya S; Adhya AK; Mishra SK
    BMC Cancer; 2018 May; 18(1):607. PubMed ID: 29843638
    [TBL] [Abstract][Full Text] [Related]  

  • 10. DC-SCRIPT is a novel regulator of the tumor suppressor gene CDKN2B and induces cell cycle arrest in ERα-positive breast cancer cells.
    Ansems M; Søndergaard JN; Sieuwerts AM; Looman MW; Smid M; de Graaf AM; de Weerd V; Zuidscherwoude M; Foekens JA; Martens JW; Adema GJ
    Breast Cancer Res Treat; 2015 Feb; 149(3):693-703. PubMed ID: 25663546
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sesterterpene MHO7 suppresses breast cancer cells as a novel estrogen receptor degrader.
    Zhao Y; Zhao C; Lu J; Wu J; Li C; Hu Z; Tian W; Yang L; Xiang J; Zhou H; Deng Z; Huang J; Hong K
    Pharmacol Res; 2019 Aug; 146():104294. PubMed ID: 31175940
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Upregulation of IRS1 Enhances IGF1 Response in Y537S and D538G ESR1 Mutant Breast Cancer Cells.
    Li Z; Levine KM; Bahreini A; Wang P; Chu D; Park BH; Oesterreich S; Lee AV
    Endocrinology; 2018 Jan; 159(1):285-296. PubMed ID: 29029116
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Preexisting Somatic Mutations of Estrogen Receptor Alpha (
    Dahlgren M; George AM; Brueffer C; Gladchuk S; Chen Y; Vallon-Christersson J; Hegardt C; Häkkinen J; Rydén L; Malmberg M; Larsson C; Gruvberger-Saal SK; Ehinger A; Loman N; Borg Å; Saal LH
    JNCI Cancer Spectr; 2021 Apr; 5(2):. PubMed ID: 33937624
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Neo-tanshinlactone selectively inhibits the proliferation of estrogen receptor positive breast cancer cells through transcriptional down-regulation of estrogen receptor alpha.
    Lin W; Huang J; Liao X; Yuan Z; Feng S; Xie Y; Ma W
    Pharmacol Res; 2016 Sep; 111():849-858. PubMed ID: 27491559
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Differential regulation of estrogen receptor α expression in breast cancer cells by metastasis-associated protein 1.
    Kang HJ; Lee MH; Kang HL; Kim SH; Ahn JR; Na H; Na TY; Kim YN; Seong JK; Lee MO
    Cancer Res; 2014 Mar; 74(5):1484-94. PubMed ID: 24413532
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Estrogen receptor 1 and progesterone receptor are distinct biomarkers and prognostic factors in estrogen receptor-positive breast cancer: Evidence from a bioinformatic analysis.
    Wu JR; Zhao Y; Zhou XP; Qin X
    Biomed Pharmacother; 2020 Jan; 121():109647. PubMed ID: 31733575
    [TBL] [Abstract][Full Text] [Related]  

  • 17.
    Mitobe Y; Ikeda K; Suzuki T; Takagi K; Kawabata H; Horie-Inoue K; Inoue S
    Mol Cell Biol; 2019 Dec; 39(23):. PubMed ID: 31501276
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Targeted degradation of activating estrogen receptor α ligand-binding domain mutations in human breast cancer.
    Gonzalez TL; Hancock M; Sun S; Gersch CL; Larios JM; David W; Hu J; Hayes DF; Wang S; Rae JM
    Breast Cancer Res Treat; 2020 Apr; 180(3):611-622. PubMed ID: 32067153
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Menin, a product of the MENI gene, binds to estrogen receptor to enhance its activity in breast cancer cells: possibility of a novel predictive factor for tamoxifen resistance.
    Imachi H; Murao K; Dobashi H; Bhuyan MM; Cao X; Kontani K; Niki S; Murazawa C; Nakajima H; Kohno N; Yamashita H; Iwase H; Hayashi S; Ishida T; Yamauchi A
    Breast Cancer Res Treat; 2010 Jul; 122(2):395-407. PubMed ID: 19847644
    [TBL] [Abstract][Full Text] [Related]  

  • 20. MiR-301a-3p Suppresses Estrogen Signaling by Directly Inhibiting ESR1 in ERα Positive Breast Cancer.
    Lettlova S; Brynychova V; Blecha J; Vrana D; Vondrusova M; Soucek P; Truksa J
    Cell Physiol Biochem; 2018; 46(6):2601-2615. PubMed ID: 29763890
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.